Although we validated the diagnostic accuracy of the previously identified 3-marker biosignature, other major findings from our study included the identification of a novel four-marker CSF biosignature comprising sICAM-1, MPO, CXCL8, and IFN-γ and a modified 3-marker signature (VEGF, IFN-γ, and MPO) which diagnosed TBM with promising accuracy. This evidence concerns the gene IFNG and meningeal tuberculosis.